Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...

MONTREAL, April 14, 2025 /CNW/ - Novartis Canada is pleased to announce that Fabhalta ® (iptacopan capsules) is now available across Canada for adult patients with paroxysmal nocturnal ...

Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada ...

EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...

Detailed price information for Royal Bank of Canada (RY-T) from The Globe and Mail including charting and trades.

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada Inc.